A Phase 2 interventional study of PTG-100 and Placebo in Ulcerative Colitis, sponsored by Protagonist Therapeutics, Inc.. Terminated at 98 sites in 17 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-21.
Sponsored by Protagonist Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 615 studies in Colitis, Ulcerative with a site in United States — 115 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.
Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 233rd largest by enrollment of the 499 interventional ones that give a count, is one of 27 that started in 2016, is one of 146 in phase 2, and was the 264th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →115 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States
Ages 16–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
University of Minnesota · Sites in United States
Ages 18+
Muhammad N Aslam, MD · Sites in United States
Ages 18–80
Vanda Pharmaceuticals · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
615 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 87 · Phase 2 173 · Phase 3 132 · Phase 4 33
First in 1995; this study’s year is marked. 27 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 76 across the 499 interventional studies, 198 across the 113 observational. Of the 407 that completed or were terminated, 192 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
332 of 615 have an industry lead sponsor. The 10 most frequent:
Protagonist Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.
Protagonist Therapeutics, Inc. has 1 study filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
55 of the studies in Colitis, Ulcerative with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 55 to your calendar (.ics) → With an account.
Among the 615 studies in Colitis, Ulcerative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objectives of this study are to evaluate the efficacy, safety, and tolerability of daily doses of PTG-100 in subjects with moderate to severe ulcerative colitis (UC).
This is a Phase II multi-centre, double blind, randomised, placebo-controlled, clinical study to evaluate the efficacy, safety, and tolerability of an oral peptide, PTG-100, administered as capsules for 12 weeks in subjects with moderate to severe UC.
Following screening procedures and confirmation of subject eligibility, subjects will be randomised 1:1:1:1 to one of three daily doses of PTG-100 (150, 300 or 900 mg) or placebo. Stratification will be based on subjects' prior treatment with anti-TNF agents, with a maximum of 50% of subjects with prior unsuccessful anti-TNF agent treatments. Subjects will be treated with study drug for 12 weeks. Sigmoidoscopies will be performed at the Screening Visit and on Week 12. A final Follow Up Visit will occur on Week 16, when subject has been off study treatment for 4 weeks. Clinical, safety, pharmacokinetic (PK) and pharmacodynamic (PD) parameters will be evaluated on an ongoing basis during the 16 week study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low dose
Drug: PTG-100
Medium dose
Drug: PTG-100
High dose
Drug: PTG-100
Placebo control
Drug: Placebo
Daily dosing of PTG-100 by subject for a 12 week treatment period.
Daily dosing of Placebo capsules by subject for a 12 week treatment period.
Proportion of Subjects Receiving PTG-100 With Clinical Remission at Week 12 Compared With Placebo
The primary efficacy endpoint for this study was the proportion of subjects receiving PTG-100 with clinical remission at Week 12. Clinical remission was defined using the Mayo subscores of stool frequency, rectal bleeding, and endoscopy.
Time frame: 12 week treatment period
| Milestone | PTG-100 (150 mg QD) | PTG-100 (300 mg QD) | PTG-100 (900 mg QD) | Placebo Group |
|---|---|---|---|---|
| Started | 25 | 25 | 23 | 25 |
| Completed | 14 | 14 | 15 | 15 |
| Not completed | 11 | 11 | 8 | 10 |
The primary efficacy endpoint for this study was the proportion of subjects receiving PTG-100 with clinical remission at Week 12. Clinical remission was defined using the Mayo subscores of stool frequency, rectal bleeding, and endoscopy.
| Participants | PTG-100 (150 mg QD) | PTG-100 (300 mg QD) | PTG-100 (900 mg QD) | Placebo Group |
|---|---|---|---|---|
| Proportion of Subjects Receiving PTG-100 With Clinical Remission at Week 12 Compared With Placebo | 1 | 2 | 3 | 4 |
Collected over Day 0 to Week 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PTG-100 (150 mg QD) | 0/25 (0%) | 2/25 (8%) | 7/25 (28%) |
| PTG-100 (300 mg QD) | 0/25 (0%) | 2/25 (8%) | 11/25 (44%) |
| PTG-100 (900 mg QD) | 0/23 (0%) | 1/23 (4.3%) | 14/23 (60.9%) |
| Placebo Group | 0/25 (0%) | 1/25 (4%) | 11/25 (44%) |
| Event | PTG-100 (150 mg QD) | PTG-100 (300 mg QD) | PTG-100 (900 mg QD) | Placebo Group |
|---|---|---|---|---|
| Colitis UlcerativeGastrointestinal disorders | 0/25 | 0/25 | 1/23 | 0/25 |
| Perirectal AbscessInfections and infestations | 1/25 | 0/25 | 0/23 | 0/25 |
| Ulcerative Colitis FlareGastrointestinal disorders | 1/25 | 0/25 | 0/23 | 0/25 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/25 | 1/25 | 0/23 | 0/25 |
| Intestinal ischemiaGastrointestinal disorders | 0/25 | 0/25 | 0/23 | 1/25 |
| Exacerbation of Ulcerative ColitisGastrointestinal disorders | 0/25 | 1/25 | 0/23 | 0/25 |
| Event | PTG-100 (150 mg QD) | PTG-100 (300 mg QD) | PTG-100 (900 mg QD) | Placebo Group |
|---|---|---|---|---|
| HeadacheNervous system disorders | 0/25 | 0/25 | 4/23 | 2/25 |
| Colitis UlcerativeGastrointestinal disorders | 3/25 | 2/25 | 3/23 | 0/25 |
| NasopharyngitisInfections and infestations | 0/25 | 3/25 | 0/23 | 1/25 |
| FatigueGeneral disorders | 0/25 | 0/25 | 2/23 | 1/25 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/25 | 0/25 | 2/23 | 0/25 |
| Abdominal PainGastrointestinal disorders | 0/25 | 2/25 | 0/23 | 0/25 |
| AnemiaBlood and lymphatic system disorders | 0/25 | 2/25 | 1/23 | 1/25 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/25 | 2/25 | 0/23 | 0/25 |
| Articular Disc DisorderMusculoskeletal and connective tissue disorders | 0/25 | 0/25 | 1/23 | 0/25 |
| Back PainGeneral disorders | 0/25 | 0/25 | 1/23 | 0/25 |
| Age, Continuous(years) | PTG-100 (150 mg QD) | PTG-100 (300 mg QD) | PTG-100 (900 mg QD) | Placebo Group | Total |
|---|---|---|---|---|---|
| Mean | 45.2 ± 13.8 | 43.8 ± 17 | 40.6 ± 14.1 | 42.2 ± 14.9 | 43 ± 15 |
| Sex: Female, Male(Participants) | PTG-100 (150 mg QD) | PTG-100 (300 mg QD) | PTG-100 (900 mg QD) | Placebo Group | Total |
|---|---|---|---|---|---|
| Female | 7 | 15 | 14 | 10 | 46 |
| Male | 18 | 10 | 9 | 15 | 52 |
| Race/Ethnicity, Customized(Participants) | PTG-100 (150 mg QD) | PTG-100 (300 mg QD) | PTG-100 (900 mg QD) | Placebo Group | Total |
|---|---|---|---|---|---|
| Race — White | 19 | 23 | 22 | 23 | 87 |
| Race — Asian | 4 | 1 | 0 | 0 | 5 |
| Race — Black or African American | 2 | 0 | 1 | 2 | 5 |
| Race — other | 0 | 1 | 0 | 0 | 1 |
| Weight(kg) | PTG-100 (150 mg QD) | PTG-100 (300 mg QD) | PTG-100 (900 mg QD) | Placebo Group | Total |
|---|---|---|---|---|---|
| Mean | 77.8 ± 16.3 | 70.7 ± 15.4 | 72.3 ± 19.1 | 69.5 ± 16.1 | 72.5 ± 16.7 |
| Height(cm) | PTG-100 (150 mg QD) | PTG-100 (300 mg QD) | PTG-100 (900 mg QD) | Placebo Group | Total |
|---|---|---|---|---|---|
| Mean | 173.2 ± 7.3 | 169.8 ± 9.7 | 173.0 ± 9.1 | 171.1 ± 8.3 | 171.7 ± 8.6 |
| BMI(kg/m^2) | PTG-100 (150 mg QD) | PTG-100 (300 mg QD) | PTG-100 (900 mg QD) | Placebo Group | Total |
|---|---|---|---|---|---|
| Mean | 25.7 ± 4.7 | 24.5 ± 5.2 | 23.9 ± 4.5 | 23.7 ± 4.7 | 24.5 ± 4.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
The record gives a start of Dec 2016, a primary completion of Mar 2018 and a completion of Mar 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2021, 2 years 11 months after primary completion. A results delay was requested in Feb 2019.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Protagonist Therapeutics, Inc.